Tags
Language
Tags
March 2024
Su Mo Tu We Th Fr Sa
25 26 27 28 29 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6

Management of Chemotherapy-Induced Nausea and Vomiting

Posted By: Underaglassmoon
Management of Chemotherapy-Induced Nausea and Vomiting

Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents
Adis | Oncology | Jan. 26 2016 | ISBN-10: 3319270141 | 181 pages | pdf | 2.91 mb

Editors: Navari, Rudolph M. (Ed.)
Provides a comprehensive review of the new agents for treatment of chemotherapy-induced nausea and vomiting
Provides a detailed description of new uses of current agents for treatment of chemotherapy-induced nausea and vomiting
Discusses an integration of the available agents for treatment of chemotherapy-induced nausea and vomiting in clinical practice


This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings.

CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients’ perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics.

This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.

Number of Illustrations and Tables
8 illus., 9 in colour
Topics
Oncology
Pharmacology / Toxicology
Pharmacotherapy

Click Here to Buy the Hardcover from Springer



Click Here for More books